Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Open Label Study to Evaluate the Safety of a Second I.P. Infusion Cycle of Catumaxomab in Patients With Malignant Ascites Due to Carcinoma, Requiring Their First Therapeutic Puncture After Treatment in the CASIMAS Study [EXTENSION OF 700040668]

Next Previous
Trial Profile

Phase II Open Label Study to Evaluate the Safety of a Second I.P. Infusion Cycle of Catumaxomab in Patients With Malignant Ascites Due to Carcinoma, Requiring Their First Therapeutic Puncture After Treatment in the CASIMAS Study [EXTENSION OF 700040668]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catumaxomab (Primary)
  • Indications Malignant ascites
  • Focus Adverse reactions
  • Acronyms SECIMAS
  • Sponsors Neovii Biotech

Most Recent Events

  • 22 Mar 2014 A phase II study (SECIMAS) in patients receiving a second treatment cycle from the CASIMA patient population is going to occur, according to information presented at ASCO 2010.
  • 22 Mar 2014 According to ClinicalTrials.gov record, up to 30 evaluable patients from the CASIMAS study were expected to be enrolled.
  • 21 Mar 2014 New source identified and integrated (European Clinical Trial register, EudraCT2009-014076-22)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top